Cannabidiol (CBD) is the most promising phytocannabinoid, owing to its non-psychotropic effects, low toxicity, and high tolerability. There are numerous proposed medical applications of CBD, including pain, epilepsy, nausea, appetite, and palliative cancer care. Before pursuing trials to evaluate the activity of CBD in a given condition, the chronic (steady state) pharmacokinetics and tolerability of CBD must be defined. Cannabinoid receptors are widely distributed throughout the central nervous system. Dogs with documented epilepsy have been shown to have elevated endocannabinoid levels in their cerebrospinal fluid, suggesting that the endocannabinoid system serves as a counter-mechanism in order to regulate the seizure threshold. This supports utilizing the endocannabinoid system as a target for the development of new treatment strategies for epilepsy.
Veterinarians will learn the difference between endocannabinoids and phytocannabinoids and their effects in the body
Veterinarians will learn about the potential therapeutic applications of CBD in veterinary patients
Veterinarians will be presented with the research that is currently needed to establish a defined therapeutic use and dose of cannabidiol